| 词条 | Basiliximab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 459525440 | width = 220px | type = mab | mab_type = mab | source = xi/o | target = CD25 | tradename = Simulect | Drugs.com = {{drugs.com|monograph|basiliximab}} | pregnancy_AU = D | pregnancy_US = B | pregnancy_category = | licence_EU = yes | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 7.2 days | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 179045-86-4 | ATC_prefix = L04 | ATC_suffix = AC02 | ATC_supplemental = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00074 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 9927MT646M | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1201439 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | C=6378 | H=9844 | N=1698 | O=1997 | S=48 | molecular_weight = 143801.3 g/mol }} Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. UsesBasiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.[1] It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.[2] Mechanism of actionBasiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[3][4] ChemistryIt is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[3][4] HistoryIt is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[4][5] References and notes1. ^MedlinePlus. Last Revised - June 15, 2012 [https://www.nlm.nih.gov/medlineplus/druginfo/meds/a612013.html Basiliximab Injection] {{Immunosuppressants}}{{Monoclonals for immune system}}{{Interleukin receptor modulators}}2. ^A.D. Katsambas, T.M. Lotti European handbook of dermatological treatments 2nd edition, 2003, page 291, {{ISBN|3-540-00878-0}} 3. ^1 Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int. 2013 Jul;26(7):662-72. {{PMID|23279211}} 4. ^1 2 Basiliximab label 5. ^Waldman, Thomas A. (2003). Immunotherapy: past, present and future. Nature Medicine 9, 269-277. 2 : Immunosuppressants|Novartis brands |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。